Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: Insights from the BEST trial

International Journal of Cardiology

Volumn 163, Issue 1, 2013, Pages 61-67

  Desai, Ravi V ^a   Guichard, Jason L ^b   Mujib, Marjan ^b   Ahmed, Mustafa I ^b   Feller, Margaret A ^b   Fonarow, Gregg C ^c   Meyer, Philippe ^d   Iskandrian, Ami E ^b   Bogaard, Herman J ^e   White, Michel ^f   Aban, Inmaculada B ^b   Aronow, Wilbert S ^g   Deedwania, Prakash ^h   Waagstein, Finn ⁱ   Ahmed, Ali ^b,j  

^a LEHIGH VALLEY HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f MONTREAL HEART INSTITUTE   (Canada)

^g NEW YORK MEDICAL COLLEGE   (United States)

^h University of California in San Francisco   (United States)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j BIRMINGHAM VA MEDICAL CENTER   (United States)

more..

Author keywords

Bucindolol; Heart failure; Morbidity; Mortality; Right ventricle

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BUCINDOLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGITALIS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; VASODILATOR AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUDDEN DEATH; SYSTOLIC HEART FAILURE; AFRICAN AMERICAN; AGED; AMBULATORY CARE; CARDIOVASCULAR MORTALITY; CHRONIC DISEASE; COMORBIDITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG FATALITY; HAZARD RATIO; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; IDIOPATHIC DISEASE; IDIOPATHIC PULMONARY HYPERTENSION; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PUBLIC HEALTH; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; VASCULAR RESISTANCE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; CHRONIC DISEASE; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, RIGHT;

EID: 84873096318     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.05.051     Document Type: Article

References (25)

1. B.J. Baker, M.M. Wilen, C.M. Boyd, H. Dinh, and J.A. Franciosa Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure Am J Cardiol 54 1984 596
2. T.G. Di Salvo, M. Mathier, M.J. Semigran, and G.W. Dec Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure J Am Coll Cardiol 25 1995 1143 1153
3. S. Ghio, A. Gavazzi, and C. Campana Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure J Am Coll Cardiol 37 2001 183 188
4. P. Meyer, G.S. Filippatos, and M.I. Ahmed Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure Circulation 121 2010 252 258
5. T.M. Ramahi, M.D. Longo, and A.R. Cadariu Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy J Am Coll Cardiol 37 2001 818 824
6. S. Provencher, P. Herve, and X. Jais Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension Gastroenterology 130 2006 120 126
7. F. Haddad, R. Doyle, D.J. Murphy, and S.A. Hunt Right ventricular function in cardiovascular disease, Part II: pathophysiology, clinical importance, and management of right ventricular failure Circulation 117 2008 1717 1731
8. The BEST investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
9. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee Am J Cardiol 75 1995 1220 1223
10. B. Hesse, T.B. Lindhardt, and W. Acampa EANM/ESC guidelines for radionuclide imaging of cardiac function Eur J Nucl Med Mol Imaging 35 2008 851 885
11. B.V. Manno, A.S. Iskandrian, and A.H. Hakki Right ventricular function: methodologic and clinical considerations in noninvasive scintigraphic assessment J Am Coll Cardiol 3 1984 1072 1081
12. S.A. Hunt, W.T. Abraham, and M.H. Chin ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 112 2005 e154 e235
13. J.K. Ghali, H.J. Krause-Steinrauf, and K.F. Adams Gender differences in advanced heart failure: insights from the BEST study J Am Coll Cardiol 42 2003 2128 2134
14. M. Packer, M.R. Bristow, and J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355
15. M. Packer, A.J. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
16. The MERIT-HF Investigators Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
17. The CIBIS-II Investigators The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
18. M.D. Flather, M.C. Shibata, and A.J. Coats Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225
19. P. Andreka, N. Aiyar, and L.C. Olson Bucindolol displays intrinsic sympathomimetic activity in human myocardium Circulation 105 2002 2429 2434
20. J.M. Cruickshank The xamoterol experience in the treatment of heart failure Am J Cardiol 71 1993 61C 64C
21. R.E. Hershberger, J.R. Wynn, L. Sundberg, and M.R. Bristow Mechanism of action of bucindolol in human ventricular myocardium J Cardiovasc Pharmacol 15 1990 959 967
22. K. Brixius, A. Bundkirchen, B. Bolck, U. Mehlhorn, and R.H. Schwinger Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium Br J Pharmacol 133 2001 1330 1338
23. M.R. Bristow, G.A. Murphy, and H. Krause-Steinrauf An {alpha}2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the {beta}-Blocker bucindolol in chronic heart failure Circ Heart Fail 3 2010 21 28
24. J.N. Cohn, M.A. Pfeffer, and J. Rouleau Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) Eur J Heart Fail 5 2003 659 667
25. R. Benza, R. Biederman, S. Murali, and H. Gupta Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension J Am Coll Cardiol 52 2008 1683 1692